PARIS — Tilak Healthcare, a leader in digital health solutions for chronic eye disease monitoring, announced that it has received a positive opinion from the French National Health Authority (Haute Autorité de Santé, HAS) granting exceptional reimbursement for its flagship product, Odysight, through the PECAN (Prise En Charge Anticipée des dispositifs médicaux Numériques – Early Access to Digital Medical Devices) program.
Odysight, a CE-marked digital medical device, enables remote monitoring of chronic maculopathies by allowing patients to perform vision tests on smartphones or tablets. Test results are automatically transmitted to physicians, who receive alerts when a decline in visual acuity is detected, enabling timely intervention and personalized care between consultations.
“The reimbursement of Odysight is a recognition of our vision and the culmination of years of collective work. We thank public authorities, our partners, physicians, and patients for their trust. We are thrilled to share our innovation more widely and make it accessible to as many patients as possible. This recognition reinforces our position as the French and European leader in ophthalmology telemonitoring. We will now focus on expanding our scientific evidence base to demonstrate the clinical impact of our innovations, with the goal of becoming the global leader in at-home monitoring of visual disorders and strengthening new strategic alliances that create real value,” said Edouard Gasser, co-founder and CEO of Tilak Healthcare.
Odysight has already been adopted by more than 30,000 patients and 1,200 doctors across France. Clinicians emphasize its ability to improve care pathways and enhance physician-patient engagement. “Odysight has demonstrated its positive impact on patient care pathways. It is a reliable, simple, and engaging tool for patients, while providing physicians with essential telemonitoring for close follow-up of chronic visual conditions,” said Dr. Vincent Dedes, Ophthalmologist and President of the SNOF (National Union of Ophthalmologists).
Since February 8, 2022, Odysight has been part of France’s Article 51 experimental program evaluating its impact on healthcare pathways. The HAS decision follows positive conclusions from that trial, along with favorable opinions from the CTIS and CSIS in November 2024, certification by the French Digital Health Agency (ANS), and growing clinical evidence demonstrating its effectiveness.
“For a long time, the ‘Amsler grid on the fridge’ was the only option for home vision monitoring. Odysight is a clinically validated, easy-to-use, and fun application that has drastically improved patient follow-up at home. The patient–physician connection is greatly strengthened, allowing for early consultations in case of confirmed visual acuity decline,” said Suehanna Nagi, President of the AMD Association.
The reimbursement milestone marks a major step in integrating digital ophthalmology tools into standard healthcare practice in France and reinforces Tilak Healthcare’s leadership in the field of vision telemonitoring.
